187 related articles for article (PubMed ID: 30151637)
1. Isolation and Characterization of Cross-Neutralizing Human Anti-V3 Single-Chain Variable Fragments (scFvs) Against HIV-1 from an Antigen Preselected Phage Library.
Kumar R; Kumari R; Khan L; Sankhyan A; Parray HA; Tiwari A; Wig N; Sinha S; Luthra K
Appl Biochem Biotechnol; 2019 Mar; 187(3):1011-1027. PubMed ID: 30151637
[TBL] [Abstract][Full Text] [Related]
2. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.
Kumar R; Andrabi R; Tiwari A; Prakash SS; Wig N; Dutta D; Sankhyan A; Khan L; Sinha S; Luthra K
BMC Biotechnol; 2012 Nov; 12():87. PubMed ID: 23153214
[TBL] [Abstract][Full Text] [Related]
4. CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.
Kumar S; Kumar R; Khan L; Makhdoomi MA; Thiruvengadam R; Mohata M; Agarwal M; Lodha R; Kabra SK; Sinha S; Luthra K
Front Immunol; 2017; 8():1568. PubMed ID: 29187855
[TBL] [Abstract][Full Text] [Related]
5. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
6. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
[TBL] [Abstract][Full Text] [Related]
9. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
10. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
Laisney IL; Strosberg AD
Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
[TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.
Maruta Y; Kuwata T; Tanaka K; Alam M; Valdez KP; Egami Y; Suwa Y; Morioka H; Matsushita S
Jpn J Infect Dis; 2016 Sep; 69(5):395-404. PubMed ID: 26902223
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.
Kirby KA; Ong YT; Hachiya A; Laughlin TG; Chiang LA; Pan Y; Moran JL; Marchand B; Singh K; Gallazzi F; Quinn TP; Yoshimura K; Murakami T; Matsushita S; Sarafianos SG
FASEB J; 2015 Jan; 29(1):70-80. PubMed ID: 25351987
[TBL] [Abstract][Full Text] [Related]
13. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
14. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
15. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
16. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
[TBL] [Abstract][Full Text] [Related]
17. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
18. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
[TBL] [Abstract][Full Text] [Related]
19. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
20. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
